View details of this raise on Seedstage

Huntington, NY

Advancing clinical trials and commercial readiness for a biotech platform targeting early-stage inflammatory conditions.

• Platform-based approach: Targeting multiple disease categories with one therapeutic strategy.
• Regulatory advantage: Using FDA’s 505(b)(2) path to accelerate development timelines.
• Strong IP portfolio: Over 60 global patents granted or pending across 23 countries.
• Validated partnerships: Collaborations with Duke University, NIDA, and KVK-Tech.
• Experienced leadership: Team with over $700M in prior exits and deep pharmaceutical expertise.

Sen-Jam Pharmaceutical is raising funds to execute Phase 2 clinical trials for its lead drug candidates targeting inflammation-related conditions. The company is developing a platform of oral anti-inflammatory therapeutics that repurpose existing FDA-approved molecules, allowing for an accelerated path to market via the 505(b)(2) regulatory route. This approach supports faster commercialization while maintaining a lower risk profile. With a pipeline spanning 11 assets and strong intellectual property coverage in over 23 countries, the company is focused on conditions where inflammation is a primary driver, such as respiratory infections, opioid withdrawal, and metabolic dysfunction. The goal of this offering is to support clinical validation of their lead programs and position the platform for strategic licensing opportunities.

The funds raised will help Sen-Jam prove the viability and demand for its PAIR (Pleiotropic Anti-Inflammatory Regulators) platform among potential pharmaceutical partners and institutional investors. The company’s business model emphasizes platform licensing rather than direct-to-consumer sales, targeting upfront payments, milestone achievements, and royalty agreements. The leadership team brings extensive experience with prior exits and deep expertise in pharmacology and regulatory strategy. Backed by partners including Duke University, KVK-Tech, and NIDA, Sen-Jam aims to redefine how inflammatory conditions are treated, shifting from reactive symptom management to early-stage intervention. This fundraising effort is intended to enable clinical progress and commercial positioning in a global market where inflammation-related diseases represent a growing economic and public health burden.

Company Info

Sen-Jam Pharmaceutical develops oral therapeutics targeting the root causes of inflammation across a broad spectrum of diseases using proprietary technology.

Sen-Jam Pharmaceutical is a biotechnology company focused on redefining inflammatory care by addressing the root causes of inflammation rather than merely treating symptoms. Through its proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) Technology, the company develops oral therapeutics designed to modulate the body’s immune response without suppressing it, targeting a wide range of diseases such as respiratory infections, metabolic disorders, and opioid withdrawal. The company aims to deliver broad-spectrum, low-side-effect, and fast-to-market solutions by repurposing FDA-approved molecules and leveraging the 505(b)(2) regulatory pathway.

With over 60 patents granted or pending in 23 countries, Sen-Jam has built a diversified pipeline of 11 assets, including multiple Phase 2-ready programs. The company partners with organizations like Duke University, NIDA, and KVK-Tech to advance clinical studies and manufacturing. Its go-to-market strategy focuses on licensing its therapeutics to pharmaceutical partners, enabling revenue through upfront payments, royalties, and milestone achievements. Sen-Jam positions itself at the convergence of innovation, clinical science, and scalable healthcare economics to transform how inflammatory diseases are addressed globally.